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Abstract
Background: Prostatitis is an inflammation of the prostate gland which affects
approximately 10% of men. Despite its frequency, diagnosing prostatitis and
monitoring patient response to treatment remains frustrating. As the prostate
contributes a substantial percentage of proteins to seminal plasma, we hypothesized
that a protein biomarker of prostatitis might be found by comparing the seminal
plasma proteome of patients with and without prostatitis.
Results: Using mass spectrometry, we identified 1708 proteins in the pooled seminal
plasma of 5 prostatitis patients. Comparing this list to a previously published list of
seminal plasma proteins in the pooled seminal plasma of 5 healthy, fertile controls
yielded 1464 proteins in common, 413 found only in the control group, and 254
found only in the prostatitis group. Applying a set of criteria to this dataset, we
generated a high-confidence list of 59 candidate prostatitis biomarkers, 33 of which
were significantly increased in prostatitis as compared to control, and 26 of which
were decreased. The candidates were analyzed using Gene Ontology and Ingenuity
Pathway analysis to delineate their subcellular localizations and functions.
Conclusions: Thus, in this study, we identified 59 putative biomarkers in seminal
plasma that need further validation for diagnosis and monitoring of prostatitis.
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Background
Prostatitis is a very common condition, with symptoms affecting approximately 10% of
all men [1]. Asymptomatic prostatitis likely affects many more men. Prostatitis is the
most common urologic diagnosis in males younger than 50 years, and the third most
common diagnosis in males older than 50. Annually, prostatitis accounts for approxi-
mately 2 million outpatient visits to urology practices in the United States alone [2].
The symptoms associated with prostatitis are extremely variable in location, severity,
duration and type. The symptom complex includes increased urinary frequency,
urgency, and dysuria, as well as pain in the pelvic region, penis and urethra. The symp-
toms range from mild to disabling and may be of limited duration, or chronic, with
episodic worsening. With such a variable phenotype, it is not surprising that prostatitis
is a challenge to diagnose and treat.
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tion has been associated with male infertility through a mechanism involving inflam-
matory cytokines and their negative impact on fertility [3,4].
Currently, prostatitis is diagnosed using symptom questionnaires, digital rectal exam,
and by culturing urine samples and expressed prostatitis secretions.
Despite the National Institutes of Health classification system [5], diagnosing prosta-
titis remains confusing and frustrating to urologists, as many of the symptoms overlap.
Moreover, diagnostic tests fail to reliably differentiate one typeo fp r o s t a t i t i sf r o m
another, and even fail to distinguish prostatitis from healthy asymptomatic individuals
[6]. There are no biomarkers to diagnose this condition accurately or to follow the
course of therapy.
One potential method for diagnosing prostatitis involves testing bodily fluids for bio-
markers of the disease. As prostatic secretions form a substantial proportion (25%) of
the semen, seminal plasma is an excellent fluid to search for such markers of prostatic
inflammation. The rest of the seminal plasma is produced by the seminal vesicles
(65%), testes and epididymis (10%), and periurethral glands (minimal) [7].
Prostatic proteins can enter semen through several pathways including: 1) normal
secretory pathways; 2) release of membrane-bound structures in seminal plasma called
prostasomes; and 3) via epithelial shedding in which abraded epithelial cells shed their
protein content into seminal plasma [8]. The latter pathway results in intracellular pro-
teins entering the semen, and holds enormous potential in identifying biomarkers of
diseases affecting specific tissues, by analyzing the proteins leaked from cells of those
tissues. In fact, the most commonly used biomarker for prostate diseases, prostate-
specific antigen (PSA), in wide use as a biomarker of prostate cancer, was originally
found and isolated from the semen [9].
There have been previous attempts to identify biomarkers of prostatitis in the semen.
Several studies have examined the presence of leukocytes or bacteria in semen of men
with prostatitis [10-13]. However, the vast majority of prostatitis is abacterial (or at
least non-cultureable), and increased leukocytes in the semen can be due to inflamma-
tion at other locations within the male urogenital tract [13]. Furthermore, leukocytos-
permia is unable to detect all cases of urogenital inflammation, and hence other
markers are needed for an accurate diagnosis of inflammation specific to the prostate
gland [14].
Other studies have investigated the potential of inflammatory proteins and cytokines
as prostatitis biomarkers. Specifically, interleukin-8 [15-17], interleukin-6 [17], interleu-
kin-10, immunoglobulin-A [18], elastase [12,19], peroxidase-positive leukocytes [19],
and nerve growth factor [20] were found to be significantly altered in the seminal
plasma of patients with prostatitis or chronic pelvic pain syndrome. However, none of
these proteins is definitive in arriving at a diagnosis.
T h e r eh a v eb e e nn oe x t e n s i v es t u d i e so nt h ep r o t e i nc o m p o s i t i o no fs e m e ni nm e n
with prostatitis. The above studies measured levels of certain inflammatory proteins,
making it possible that potential biomarkers which are not directly measured would
have been missed.
There are very few studies on semen proteins: Pilch and Mann found 923 proteins in
the semen of a healthy man [8]. We recently performed mass spectrometry on semen
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mately 2300 unique proteins [21].
We hypothesized that seminal plasma from men with prostatitis may contain notice-
ably different concentrations of specific proteins that could be used as biomarkers to
diagnose prostatitis and monitor its response to treatment. In addition to the above, a
prostatitis biomarker would be invaluable in distinguishing prostatitis from other
causes of increased serum PSA levels, decreasing unnecessary anxiety and invasive
investigations for men with elevated PSA [22,23].
By using a shotgun proteomic approach, we compared the proteomes of seminal
plasma from men with confirmed prostatitis to the proteomes of seminal plasma from
fertile, healthy controls [21]. Seminal plasma samples from 5 individuals from each of
the two diagnostic groups were pooled together to account for inter-individual varia-
tion in protein composition. Using this approach, we compiled a list of candidate pros-
tatitis biomarkers and verified two of them using an ELISA assay.
Results and discussion
LC-MS analysis
Following trypsin digestion, each replicate was fractionated using SCX liquid-chroma-
tography to increase the number of peptides identified in each fraction. Three repli-
cates were analyzed in order to gauge reproducibility, as well as to increase protein
identification and prediction confidence. The first 10 fractions from SCX were analyzed
using an 88 min gradient and the next 11 fractions were analyzed using a 55 min gra-
dient, since the first 10 fractions had greater sample complexity, allowing for more
peptide identifications (data not shown).
Data analysis
Data was searched with Mascot and X!Tandem to increase sequence coverage and the
number of proteins identified. Search results were merged using Scaffold 2.0 in MudPit
mode for analysis and visualization. Mascot and X!Tandem filter settings were adjusted to
achieve a FPR of 1.1-1.5%. A triplicate sample dataset was uploaded into Scaffold. The ori-
ginal Scaffold file (Prostatitis.sfd) can be downloaded from Tranche (http://www.Proteo-
meCommons.org) hash code: AAlPx7YK40+620DDQaBE2qOoMTkT7LqKHsEDFO/pc/
WDtaIRrYEn9bIEAtQ+7q7WPGOGZhDmSebpgfJbUEdHg6pNUXQAAAAAAAAC
jQ==).
In triplicate analysis of the Prostatitis group we found a total of 1708 proteins
(including 9 proteins that matched rever s es e q u e n c e s )a taF P Ro f1 . 1 %w i t h1 4 4 9 ,
1357 and 1157 proteins in each replicate (Figure 1, Additional File 1).
Comparison of Control and Prostatitis protein lists
Comparing Control and Prostatitis proteomes, there are 1464 proteins in common, 413
found only in Control and 254 found only in Prostatitis (Figure 2, Additional File 2). In
total, we identified 2131 proteins (including 12 proteins that matched reverse
sequences) in the combined Control and Prostatitis groups with a FPR of 1.1%. The
spectrum report for the Prostatitis dataset m a yb eo b t a i n e db yf o l l o w i n gt h ei n s t r u c -
tions outlined in Additional File 3.
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evaluated and removed from further analysis. Spectral counting is a semi-quantitative
method with the advantage of having a linear dynamic range of several orders of magni-
tude [24]. Due to the inherent limitations of this quantitative method which include poor
sensitivity to small changes in abundance (or sensitivity to fold changes greater than
100%) and diminished quantitative accuracy of proteins identified by very few counts
[24,25], the following criteria were used to select a high-confidence list of potential pro-
teins with significantly increased concentration in one of the groups: a) Fold differences
Figure 1 Venn diagram representing overlap of identified proteins among triplicate seminal
plasma samples in prostatitis patients. 1708 proteins identified in total.
Figure 2 Venn diagram representing overlap of proteins identified in prostatitis vs control (21)
diagnostic groups.
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Page 4 of 20must be greater than or equal to 2; b) The coefficient of variation (CV) for the 3 replicates
must be less than or equal to 50% if the average spectral count value is > 5; c) If one clini-
cal group has a spectral count average ≤ 5, then a CV of less than 100% for that group was
accepted; d) If one clinical group has zero spectral counts, then the other clinical group
must have an average spectral count > 5; e) If one clinical group has an average spectral
count < 10, then the other must have an average spectral count > 10. By applying the
above mentioned selection criteria, we found the following: 33 proteins were significantly
increased in prostatitis as compared to controls (Table 1), and 26 proteins were signifi-
cantly increased in controls as compared to prostatitis (Table 2).
Table 1 List of candidate biomarker proteins found at higher abundance in prostatitis
compared to control, according to spectral counting.
Gene Name Average Spectral Count Fold Change* Prostatic Origin**
Control Prostatitis
ALB 1441 3079 2.1
SERPINA1 149 382 2.6 Yes
CST4 83 468 5.7
CST3 65 202 3.1 Yes
PAEP cDNA FLJ52183 52 144 2.8
C4A 38 131 3.5 Yes
A2M 44 103 2.3 Yes
SERPINA5 37 122 3.3
C3 34 104 3 Yes
LPL 30 66 2.2
IGHG2 17 46 2.6
A1BG 25 50 2
MSLN 16 33 2
SERPING1 17 48 2.9
SCPEP1 17 44 2.6 Yes
GLA 21 43 2 Yes
OLFM4 15 41 2.7 Yes
SMPD1 9 20 2.2 Yes
CTSF 9 24 2.5 Yes
SERPINF1 10 33 3.4 Yes
MINPP1 9 19 2.1 Yes
CFI 9 18 2.1
CTSC 5 10 2.2
CST6 7 15 2.2 Yes
TXNDC16 8 18 2.3 Yes
LCN1 2 15 6.3
COL6A2 3 15 5.5 Yes
A4GALT 4 15 4 Yes
PATE4 4 13 3 Yes
TIMP3 5 11 2.1
CST2 2 16 9.6
FGB 4 11 2.6
COMP 4 12 2.9
* Fold change = average prostatitis/average control
** Protein/gene name annotated as expressed in the prostate in at least 2 out of 3 databases (BioGPS; Unigene, Protein
Atlas)
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were searched against UniGene, BioGPS, and Human Protein Atlas. According to Uni-
Gene, 18 proteins had “strong” expression in the prostate, 19 had “moderate” expres-
sion in the prostate, and 12 had “weak” expression in the prostate. According to
Human Protein Atlas, 10 proteins had “strong” expression in the prostate, 11 proteins
had “moderate” expression in the prostate, 11 had “weak” expression in the prostate,
and the remainder were not expressed in the prostate. According to BioGPS, which
catalogues mRNA expression in various tissues, 19 proteins have strong gene expres-
sion in the prostate, as defined by an expression of 3 times the average tissue
expression.
The seminal plasma proteome of prostatitis patients was analyzed using ProteinCen-
ter software to ascertain the Gene Ontology (GO) annotations for molecular functions
(Figure 3), cellular components (Figure 4), and biological processes (Figure 5) for the
entire prostatitis proteome. The top 3 molecular functions were catalytic activity, pro-
tein binding, and metal ion binding. The top 3 cellular components were cytoplasm,
Table 2 List of candidate biomarker proteins found at higher abundance in control
compared to prostatitis, according to spectral counting.
Gene Name Average Spectral Count Fold Change* Prostatic Origin**
Control Prostatitis
CPM 31 10 3 Yes
DYNC1H1 29 13 2.3
MUC5B 29 7 4.2
RAB27B 21 11 2 Yes
PHGDH 20 10 2.1 Yes
CA2 19 9 2
ACO1 14 6 2.3 Yes
ANXA6 19 5 3.5
CACNA2D1 19 5 4
FAM129A 10 4 2.4 Yes
CDC42 12 4 2.7 Yes
RHOC 13 4 3.2 Yes
HGD 14 5 2.9
RAB2A 11 5 2.1 Yes
DCXR 12 6 2.1 Yes
LAMP1 10 4 2.3 Yes
ALDH9A1 11 5 2 Yes
CMPK1 13 5 2.5
NOV 13 5 2.4 Yes
NAPA 12 4 2.8 Yes
SOD3 12 5 2.3 Yes
LIFR 11 5 2.3 Yes
RNPEP 12 5 2.2 Yes
FLNB 13 4 3.2 Yes
DDAH1 12 5 2.3 Yes
KIF5B 11 4 3.1 Yes
* Fold change = average control/average prostatitis
** Protein/gene name annotated as expressed in the prostate in at least 2 out of 3 databases (BioGPS; Unigene, Protein
Atlas)
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regulation of biological processes, and response to stimulus.
To better delineate the differences between the normal seminal plasma proteome and
those of prostatitis patients, a comparison of GO annotations was performed using
ProteinCenter in which the seminal plasma proteome of healthy fertile controls [21]
Figure 3 Pie chart representing seminal plasma proteome of prostatitis patients in terms of
molecular functions.
Figure 4 Pie chart representing seminal plasma proteome of prostatitis patients in terms of cellular
components.
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Figure 8) and downregulated (Figure 9, Figure 10, Figure 11) in prostatitis. In compar-
ing the upregulated prostatitis candidates to the normal seminal plasma proteome, the
most striking differences were a 3-fold increase in the percentage of proteins involved
in enzyme regulatory activity, a 2.5-fold increase in the percentage of extracellular pro-
teins, and a 3-fold increase in the percentage of proteins involved in the defensive
response. A comparison of the candidates downregulated in prostatitis relative to the
Figure 5 Pie chart representing seminal plasma proteome of prostatitis patients in terms of
biological processes.
Figure 6 Bar graph representing comparison of candidate proteins upregulated in prostatitis vs
proteins found in normal healthy seminal plasma in terms of molecular functions.
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tage of proteins involved in catalytic activity and protein binding, a moderate (10-15%)
increase in the percentage of proteins found in the cytoplasm, Golgi apparatus, and
membrane, and a significant (20-25%) increase in the percentage of proteins involved
in development, regulation of biological processes, and transport.
Figure 7 Bar graph representing comparison of candidate proteins upregulated in prostatitis vs
proteins found in normal healthy seminal plasma in terms of cellular components.
Figure 8 Bar graph representing comparison of candidate proteins upregulated in prostatitis vs
proteins found in normal healthy seminal plasma in terms of biological processes.
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ciated with the largest number of candidate proteins are small molecule biochemistry,
molecular transport, lipid metabolism, protein degradation, and protein synthesis. The
diseases and disorders associated with the largest number of candidate proteins are
neurological disease, cancer, endocrine disorders, metabolic disease, and reproductive
Figure 9 Bar graph representing comparison of candidate proteins downregulated in prostatitis vs
proteins found in normal healthy seminal plasma in terms of molecular functions.
Figure 10 Bar graph representing comparison of candidate proteins downregulated in prostatitis
vs proteins found in normal healthy seminal plasma in terms of cellular components.
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lated candidates are acute phase response signaling, the complement system, and the
coagulation system.
Verification of Methodology
Two candidate protein biomarkers were arbitrarily chosen based on fold differences
(Table 1), putative roles in the pathogenesis of prostatitis, and the availability of assay
reagents for verification using the gold standard in protein quantification, the enzyme-
linked immunosorbent assay (ELISA). The proteins selected were mesothelin isoform 2
and cystatin C, both of which were upregulated in prostatitis samples compared to
controls. Seminal plasma from each patient who contributed a sample to the mass
spectrometric analysis was analyzed individually for mesothelin isoform 2 (Figure 12)
and cystatin C concentrations (Figure 13). For mesothelin isoform 2, every sample
from the Prostatitis group had a higher concentration than every sample from the
Control group, and a mean concentration nearly 3 times greater in the Prostatitis
group as compared to the Control group. Statistical analysis using a two-tailed Mann
Whitney test found this difference to be significant (p = 0.0079). Similarly, Cystatin C
was significantly increased in concentration in the seminal plasma of patients with
prostatitis (p = 0.0159), although the difference was not as drastic. These results sup-
port our data obtained through mass spectrometric analysis, and suggest that the other
candidates identified are likely upregulated or downregulated in prostatitis as compared
to healthy fertile males. The discrepancy in fold change may be a consequence of the
semi-quantitative nature of spectral counting with mass spectrometry, and reflects the
need for future validation of other candidate biomarkers, using multiple reaction moni-
toring (MRM) or ELISA.
Figure 11 Bar graph representing comparison of candidate proteins downregulated in prostatitis
vs proteins found in normal healthy seminal plasma in terms of biological processes.
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significance (p < 0.05) as determined by two-tailed Mann Whitney test.
Figure 13 Box plot representing ELISA candidate verification of cystatin C. * denotes significance (p
< 0.05) as determined by two-tailed Mann Whitney test.
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Of the 33 proteins increased in prostatitis, 26 were determined to be expressed in the
prostate gland, according to at least one of three databases searched (UniGene,
BioGPS, and the Human Protein Atlas). The 7 proteins that were not expressed in the
prostate according to these databases included cystatin-S, cystatin-SA and lipocalin-1.
However, cystatin-S gene expression in the prostate gland, as well as in other tissues of
the male genitourinary system, has been reported [26]. As well, lipocalin-1, the major
protein found in human tear fluid, has similarly been shown to be expressed in the
prostate [27]. Thus, out of 33 candidate proteins from seminal plasma found to be
increased in prostatitis, 28 are known to be produced in the prostate gland.
Protease inhibitors form a large proportion of the proteins found to be increased in
the seminal fluid of prostatitis patients. The majority of these are members of the
cystatin superfamily of secreted cysteine protease inhibitors, specifically the type 2
cystatin family. The type 2 cystatins found to be upregulated in prostatitis patients in
our study are cystatin S, cystatin C, cystatin M, and cystatin SA. Other type 2 cystatins
were previously found to be involved in processes such as spermatogenesis in the male
reproductive tract, but those cystatins were not identified in our study [28]. While pre-
vious work on type 2 cystatins classifies their function as anti-inflammatory, and indi-
cates that they are downregulated in inflammatory responses, conflicting evidence
suggests that their regulation may not be so simple. Cystatin-C, a cysteine protease
inhibitor, has been shown to be upregulated in Sjogren’s syndrome, which is a para-
digm of autoimmunity and inflammation [29]. Studies on inflammatory skin disorders
also found increased levels of cystatin M/E in the spinous cell layers of inflammatory
lesions, which, they speculated, might help control increased levels of cysteine pro-
teases during inflammation and infection [30]. Similarly, production of cystatin-SA is
enhanced by nuclear factor -light-chain enhancer of activated B cells (NFB), an
intracellular signaling molecule activated by pro-inflammatory cytokines [31]. Cystatin-
SA, in turn, increases interleukin-6 production, which is a pleiotropic cytokine with
many pro-inflammatory functions. One potential explanation for the upregulation of
anti-inflammatory type 2 cystatin proteins in prostatitis is the body’s attempt to regu-
late the inflammatory response and prevent excessive tissue destruction, similar to the
case of activation of hemostatic pathways, which activate fibrinolytic proteins to pre-
vent excessive clotting. Notably, none of the type 2 cystatins has previously been inves-
tigated as a biomarker of prostatitis, suggesting that they represent a promising target
for future investigations.
Other protease inhibitors found to be increased in the seminal plasma of prostatitis
patients in our study include SERPINA1 (alpha-1-antitrypsin), SERPINA5, SERPING1,
SERPINF1, Lipocalin-1, and TIMP3. As with the type 2 cystatins, the literature gener-
ally characterizes these proteins as anti-inflammatory; however, this does not preclude
their upregulation during inflammation. Lipocalin-1, for example, is another cysteine
protease inhibitor that has been documented to be overexpressed during periods of
stress, inflammation, or infection [32]. With the exception of SERPINA1, which has
been found in histopathological studies of granulomatous prostatitis [33], none of
these protease inhibitors have been studied in the context of prostatitis.
Other candidate biomarker proteins found in our experiments have functions more
consistent with those expected to be upregulated during inflammation. Olfactomedin-4,
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tory bowel disease [34], and is also induced by NFB in myeloid precursor cells, suggest-
i n gt h a ti tf o r m sp a r to fap r o - i n f l a m m a t ory signaling network [35]. Alpha-2-
macroglobulin and fibrinogen beta chain are acute phase proteins, which are known to
be strongly upregulated during inflammation and other stresses [36]. Complement com-
ponent C3 is a central player in the complement system, which is one of the major
enzyme cascades activated during infection and inflammation [37]. Sphingomyelin phos-
phodiesterase isoform 1 has been described as strongly pro-inflammatory [38]. Mesothe-
lin isoform 2, while not associated with inflammation in the literature, has been
proposed as a biomarker to distinguish pancreatitis from pancreatic cancer [39]. Such a
protein would be invaluable in differentiating other inflammatory and neoplastic pro-
cesses (i.e. prostatitis and prostate cancer).
Of our 33 candidate biomarkers that were increased in prostatitis, only 5 have pre-
viously been studied for prostatitis diagnosis. Complement component C3 levels in
seminal plasma were found to help distinguish chronic prostatitis and leukocytosper-
mia from controls [12]. Urinary alpha-2-macroglobulin and albumin were investigated
for possible utility in diagnosing acute prostatitis, and the ratio of alpha-2-macroglobu-
lin:albumin was found to be a highly sensitive diagnostic test for acute prostatitis [40].
Furthermore, including other urinary parameters in a stepwise multinomial logistic
regression analysis provides optimal differentiation between acute pyelonephritis and
acute prostatitis [40]. Both SERPINA1 [33] and fibrinogen beta chain [41] have been
found to be increased in prostatitis tissue obtained through biopsy, but the invasiveness
of such a procedure is precisely what we are trying to avoid, by searching for a seminal
plasma diagnostic biomarker. All of these previously investigated proteins are all quin-
tessential pro-inflammatory proteins, which reflect our current understanding of pros-
tatitis as an inflammatory disease of the prostate. By using a mass spectrometry
approach to identify large numbers of proteins of diverse function, we can find pro-
teins whose functions may be unrelated to inflammation, or are as yet unknown, but
which still may function as biomarkers of prostatitis.
Comparing the candidates upregulated in prostatitis to the overall seminal plasma
proteome in healthy fertile controls, reveals a striking 3-fold increase in the percentage
of proteins annotated as possessing enzyme regulator activity, which is consistent with
the number of candidates that regulate the inflammatory response. In terms of subcel-
lular localization, the upregulated prostatitis candidates show an almost 3-fold increase
in percentage of extracellular proteins, with a concomitant decrease in the number of
cytoskeletal, cytosolic, and membrane proteins. Notably, while the percentage of mem-
brane proteins in prostatitis patients’ seminal plasma is decreased, compared to normal
seminal plasma, it is still over 40% of the prostatitis candidates, which may reflect the
cellular destruction in prostatitis and the release of membrane proteins into the semi-
nal plasma. The biological processes of the seminal plasma proteomes from prostatitis
vs control patients show a 3-fold increase in proteins involved in the defense response
and coagulation, which supports our understanding of prostatitis as an inflammatory
process. A moderate decrease (15%) in the percentage of proteins involved in cell orga-
nization and biogenesis is also noted, which may reflect the changing priorities of cells
during an inflammatory response as compared to normal.
Kagedan et al. Clinical Proteomics 2012, 9:2
http://www.clinicalproteomicsjournal.com/content/9/1/2
Page 14 of 20Proteins Decreased in Prostatitis
A prostatitis biomarker could also be a protein that is decreased in the seminal plasma
of prostatitis patients as compared to controls. Of our 59 candidate biomarkers, 26
were decreased in the seminal plasma of men with prostatitis. 25 of these were
expressed in the prostate gland, according to at least one of three databases searched
(UniGene, BioGPS, and the Human Protein Atlas). The one remaining protein is CAC-
NA2D1, a voltage-dependent calcium channel subunit, which is not expressed in the
prostate but is expressed in the testes (Unigene).
Candidate proteins which bear mention include SOD3 extracellular superoxide dis-
mutase, which has been shown to be highly anti-inflammatory, inhibiting inflammatory
cell migration by preventing fragmentation of hyaluronic acid [42]. Thus, the downre-
gulation of SOD3 is consistent with prostatitis being a disease of inflammation. More-
over, previous studies have demonstrated that SOD3 levels in the seminal plasma are
constant between fertile controls and vasect o m i z e dm e n ,i n d i c a t i n gt h a ti to r i g i n a t e s
proximal to the site of ligation of the vas deferens, likely the prostate [43]. Taken
together, this suggests that SOD3 has potential in the diagnosis and monitoring of
inflammatory diseases of the prostate.
Several other downregulated candidate proteins have been previously described as
possessing pro-inflammatory properties. The most plausible explanation for this obser-
vation is the complex interplay between pro- and anti-inflammatory factors, resulting
in a response that is carefully regulated and controlled. It is possible that our downre-
gulated pro-inflammatory proteins are responding to regulatory signals, ensuring that
the inflammation does not spiral out of control. Such pro-inflammatory proteins found
in our study include Mucin-5b, which has been shown to be upregulated in inflamed
nasosinus mucosa [44] and in chronic rhinosinusitis [45]. As well, Filamin-B, which
functions to recruit inflammatory cells to the site of inflammation, was found to be
decreased in expression [46].
Other noteworthy proteins include NOV and L-xylulose reductase, both of which are
decreased in prostatitis, but which previous investigations have found to be increased
in prostate cancer [47,48]. Both of these proteins could potentially be invaluable in dis-
tinguishing prostate cancer from prostatitis, which is currently a major confounder in
the diagnosis of cancer.
Comparing the GO annotations of candidates downregulated in prostatitis to the
normal seminal plasma proteome produced less striking results than the upregulated
prostatitis candidates. This may reflect the fact that cells downregulate proteins of
varying functions and localization during an inflammatory response, while upregulating
proteins of a single function (i.e. defense). Compared to the normal seminal plasma
proteome, the downregulated prostatitis candidates had moderate increases in the per-
centage of proteins involved in catalytic activity and protein binding. Downregulated
prostatitis candidates also had increased percentages of proteins involved in regulation
of biological processes, suggesting that while some regulatory proteins increase during
prostatitis, others decrease. Notably, none of the downregulated prostatitis candidates
were involved in the defense response, suggesting that prostatitis causes defensive pro-
teins to be upregulated, not downregulated.
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We identified 59 proteins whose significantly differential expression in the seminal
plasma of prostatitis patients suggests that they may have potential as biomarkers of
prostatitis. Such proteins would have application in the diagnosis of prostatitis, as well
as in monitoring response to treatment. Furthermore, improved methods of diagnosing
prostatitis would better distinguish prostatitis from more serious causes of elevated
PSA, such as prostate cancer, and reduce the need for unnecessary anxiety and invasive
investigations. As well, diagnosing prostatitis could help better elucidate the cause of a
patient’s infertility. Many of our candidate biomarkers have previously been reported
to be involved in inflammatory pathways, which correlate with our understanding of
prostatitis as a disease of inflammation. A better understanding of the functions of
these proteins may help to discover the pathogenesis of prostatitis, and improve our
methods of treating it.
Methods
Seminal plasma samples were collected, processed, and analyzed in accordance with
the methods described elsewhere [21]. A brief summary of the methods for the Prosta-
titis and Control samples is given below.
Sample Collection and Processing
Semen from men with prostatitis was collected after a minimum of 3 days of sexual
abstinence. Our 5 patients all had confirmed prostatitis, as diagnosed by the presence
of lower urinary tract symptoms (frequency, urgency, dysuria), pain in the pelvic
region, and prostatic tenderness on digital rectal examination. Samples were allowed to
liquefy, centrifuged, and the supernatant (seminal plasma) was stored for further analy-
sis. Total protein concentration was measured using the Biuret assay. Five prostatitis
seminal plasma samples were combined to make a “Prostatitis” pool with 3 mg total
protein per experiment. Each sample contributed an equivalent amount of protein to
the total pooled protein.
Trypsin Digestion
Three “Prostatitis” replicate pools were denatured with urea, reduced with dithiothrei-
tol and alkylated with iodoacetamide. Samples were then desalted, frozen and partially
lypohilized. The samples were left to digest overnight using modified porcine trypsin
(1:50, trypsin: protein concentration, Promega). Digestion was stopped the following
morning by acidifying the solution with formic acid.
Strong-Cation Exchange Liquid Chromatography
Samples were fractionated using an Agilent 1100 High Performance Liquid Chromato-
graphy (HPLC) system equipped with a strong-cation exchange (SCX) PolySUL-
FOETHYL A column (The Nest Group, Inc.). Sixty fractions were collected. Fractions
31 to 49 were stored individually, while fractions 26-30 and 50-54 were pooled
together (total 21 fractions).
Mass Spectrometry
Twenty-one SCX fractions from each of the three Prostatitis replicates were further
fractionated using nano-flow reverse-phase chromatography on a Proxeon EASY-nLC
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Scientific, San Jose, California). For more details of the method, please see Batruch et
al. [21]. The Orbitrap was used to acquire a full MS1 scan followed by six MS2 scans
in the linear-ion trap (LTQ). Only charge states of 2+ and 3+ were subjected to
fragmentation.
Data analysis
X!Calibur RAW files were uploaded into Mascot Daemon (Matrix Science, London,
UK, v.2.2) to create Mascot Generic Files (MGF). These were then searched against a
concatenated forward and reverse IPI.Human v.3.54 database with Mascot (v.2.2) and
X!Tandem (Global Proteome Machine Manager, version 2006.06.01) with a parent tol-
erance of 7 ppm and fragment tolerance of 0.4 Da. The following modifications were
used in searches: one missed cleavage allowed, fixed carbamidomethylation of cysteines
and the following variable modifications: oxidation of methionines, deamidation of
asparagines and glutamines, cyclization of N-terminal glutamic and aspartic acids (pyr-
oGlu-Asp), and protein N-terminal acetylation. Search result files from Mascot and X!
Tandem were uploaded into Scaffold (Proteome Software, Portland, Oregon, v. 2.0)
and filtered using peptide thresholds to achieve a false positive rate (FPR) of ~ 1.0-
1.5%. FPR was calculated as follows: 2xFP/(FP+TP) where FP is the number of proteins
matching the reverse database and TP is the number proteins matching the forward
database.
Verification of Methodology
In order to confirm the semi-quantitative data obtained from mass spectrometric ana-
lysis of the seminal plasma samples, 2 candidate proteins were arbitrarily selected for
verification by enzyme-linked immunosorbent assay. The concentrations of cystatin-C
and mesothelin isoform 2 were measured separately using specific sandwich immu-
noassays developed with DuoSet ELISA reagents (R&D Systems Inc., MN, USA). The
cystatin-C assay employed two monoclonal antibodies, one for coating (Part 842942)
and one for detection (Part 842943). Similarly, the mesothelin isoform 2 assay used
two monoclonal antibodies, one for coating (Part 843359) and one for detection (Part
843360). All four antibodies were raised in mice. Both assays were conducted in a two-
site sequential immunometric format with time-resolved fluorescence detection. Each
assay has a detection limit of 0.1 ug/L and a dynamic range up to 10 ug/L. For each
assay, within the measurement range, precision was < 15%. All standards and samples
for both assays were measured in duplicate.
Prior to analysis, samples analyzed for cystatin-C were diluted 10,000 times in a dilu-
tion buffer consisting of 1% bovine serum albumin (BSA) in phosphate-buffered saline
(PBS) at pH = 7.2. Samples analyzed for mesothelin isoform 2 were diluted 100 times
in the same buffer.
Each well on the cystatin-C plate was incubated overnight at room temperature with
250 ng/100 uL monoclonal capture antibody in coating buffer (PBS, pH = 7.2). Each
well on the mesothelin isoform 2 plate was incubated overnight at room temperature
with 400 ng/100 uL monoclonal capture antibody in coating buffer (PBS, pH = 7.2).
The next day each plate was washed 3 times with washing buffer (PBS with 0.05%
Tween 20 at pH = 7.4). Dilution buffer (1% BSA in PBS at pH = 7.2) was then added
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washing buffer and then 100 uL of diluted samples or standards were added to each
plate. Both plates were then incubated at room temperature for 90 minutes with gentle
shaking. Each plate was then washed 6 times with washing buffer. To each well on the
cystatin-C plate, 25 ng/100 uL of biotinylated detection antibody in dilution buffer was
added. To each well on the mesothelin isoform 2 plate, 100 ng/100 uL of biotinylated
monoclonal anti-human mesothelin isoform 2 detection antibody in dilution buffer
was added. Both plates were then incubated for 1 hour at room temperature with gen-
tle shaking, then washed 6 times with washing buffer. Five ng/well of alkaline phospha-
tase-conjugated streptavidin solution (Jackson ImmunoResearch) in sample buffer was
added to each well, and allowed to incubate at room temperature for 15 minutes with
gentle shaking. Each plate was then washed 6 times with washing buffer. To each well
on both plates 100 μL of substrate buffer [0.1 mol/L Tris buffer (pH 9.1) containing
0.25 mmol/L diflunisal phosphate (DFP), 0.1 mol/L NaCl, and 1 mmol/L MgCl2]w a s
added. Both plates were then incubated at room temperature for 10 minutes with gen-
tle shaking. To each well on both plates 100 uL of developing solution (1 mol/L Tris
base, 0.15 mol/L NaOH, 2 mmol/L TbCl3, 3 mmol/L EDTA) was added and allowed
to incubate for 1 minute at room temperaturew i t hg e n t l es h a k i n gp r i o rt om e a s u r e -
ment. Protein concentration was quantified by measuring fluorescence in each well
with an Envision time-resolved fluorometer (Perkin Elmer) as previously described
[49].
Additional material
Additional File 1: Proteins identified in triplicate analysis of Prostatitis seminal plasma samples. This file
contains all proteins identified in Prostatitis group seminal plasma along with the number of spectra, number of
unique peptides and protein sequence coverage in each replicate.
Additional File 2: Proteins identified in triplicate analysis of Control and Prostatitis seminal plasma
samples. This file contains all proteins identified in Control and Prostatitis group seminal plasma along with
number of spectra in each replicate.
Additional File 3: Instructions for retrieving Additional File 3. This file contains instructions on how to
download three Spectrum report files (1of3, 2of3 and 3of3) from Tranche (http://www.ProteomeCommons.org).
The three Spectrum report files contain information about all peptides that were identified in Prostatitis group
seminal plasma, such as: strong-cation exchange fraction in which the peptide was identified, Mascot ion and X!
Tandem peptide scores, peptide modifications, observed m/z.
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